A 1,4-disubstituted piperazine-2,5-dione derivative, preparation method and application thereof

The 1,4-disubstituted piperazine-2,5-dione compounds synthesized through the framework transition strategy were evaluated using H2O2 and NMDA induction models, which solved the problem of synthesis of bistetrahydrofuran lignan compounds and achieved resistance Development of novel compounds with oxidative and neuroprotective effects.

CN115838355BActive Publication Date: 2024-12-03THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202211224348.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-08
Publication Date
2024-12-03
Estimated Expiration
2042-10-08

AI Technical Summary

Technical Problem

It is difficult to efficiently synthesize bistetrahydrofuran lignan compounds with antioxidant activity and neuroprotective effects in the prior art, and their chiral centers are complex, resulting in a change in structure and making it difficult to synthesize in large quantities.

Method used

A series of 1,4-disubstituted piperazine-2,5-dione compounds were designed and synthesized as derivatives of ditetrahydrofuran lignans using a skeleton transition strategy, and excitation induced by NMDA The sexual injury model evaluates its pro-survival, antioxidant and anti-excitation injury activities.

Benefits of technology

It was determined that compound 9a-9s had pro-survival, antioxidant and anti-excitation damage activities. Representative compound 9r exerted pro-survival and antioxidant activities through the IL-6/Nrf2 positive feedback signaling pathway, and inhibited NMDA subunit and upregulated AMPA. Protein levels inhibit excitatory damage and significantly improve neuroprotective effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115838355B_ABST
    Figure CN115838355B_ABST
Patent Text Reader

Abstract

The present invention discloses a novel 1,4-disubstituted piperazine-2,5-dione derivative, a preparation method and an application thereof. The method adopts a skeleton transition strategy to design and synthesize a series of novel 1,4-disubstituted piperazine-2,5-dione compounds as derivatives of diepoxylignans, and uses a H2O2-induced oxidative stress model and an NMDA-induced excitotoxicity injury model to evaluate the antioxidant activity and anti-excitotoxicity activity of the derivatives. It is determined that compounds 9a-9s have pro-survival, anti-oxidation and anti-excitotoxicity activities, and further clarifies that the most active representative compound 9r promotes cell proliferation and antioxidant activity through the IL-6 / Nrf2 positive feedback signaling pathway, and the representative compound 9c inhibits NMDA-induced excitotoxicity by activating the IL-6 / Nrf2 positive feedback signaling pathway, inhibits NMDA subunit NR2B and upregulates the level of AMPA, thereby inhibiting NMDA-induced excitotoxicity and promoting the proliferation and survival of undamaged cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemical synthesis, and specifically relates to a 1,4-disubstituted piperazine-2,5-dione derivative, a preparation method and an application thereof. Background Art

[0002] Oxidative stress caused by the unbalanced production of reactive oxygen species and antioxidants is a contributing factor to the onset and development of many diseases, including neurodegenerative diseases, cardiovascular diseases, cancer, stroke, and inflammation. Under physiological conditions, the level of reactive oxygen species formation is in balance with the antioxidant capacity. However, under pathological conditions, supraphysiological levels of ROS can lead to oxidative stress and subsequent biomolecular damage. When cells are stimulated by superoxide, hydrogen peroxide, and hydroxyl radicals, reactive oxygen species are generated and lead to oxidative stress. Among them, hydrogen peroxide (H2O2) is responsible for transmitting redox signals from the generation site to the target site. Therefore, it is considered the most suitable for establishing oxidative stress models.

[0003] Nrf2 is one of the important factors in anti-oxidative stress. Under normal conditions, most of Nrf2 remains in an inactive state in the cytoplasm in the form of a complex with Keap1 and is constantly targeted for degradation by ubiquitinases. However, when cells are subjected to oxidative stress, the complex between Nrf2 and Keap1 will dissociate, resulting in the accumulation of Nrf2 in the cytoplasm. When Nrf2 translocates to the nucleus and binds to the small Maf protein, the ARE (antioxidant response element) will be activated. The activated ARE further leads to the transcriptional activation of various antioxidant enzymes and proteins, including heme oxygenase-1 (HO-1) and pro-survival cytokines (such as IL-6). IL-6 is a pleiotropic cytokine that plays an important role in cell survival, proliferation, immunity, and inflammation. When cells are under oxidative stress, Nrf2 indirectly activates its promoter through ARE to mediate IL-6 expression and exert pro-survival and antioxidant activities. In turn, IL-6 reduces apoptosis and promotes cell survival by activating downstream signaling including MAPK, JAK / Stat3, and PI3K / Akt, increasing the nuclear translocation of Nrf2 or its quantification. Therefore, the development of antioxidants targeting the IL-6 / Nrf2 cross-axis may provide a new therapeutic strategy for the treatment of oxidative stress-related diseases.

[0004] Glutamate receptors are ionotropic receptors, including N-methyl-D-aspartate receptors (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazole receptors (AMPAR). Among them, NMDA receptors not only play an important physiological role in the development of the nervous system, such as regulating the survival of neurons, regulating the development of neuronal dendrites and axon structures, and participating in the formation of synaptic plasticity. It also plays a key role in the formation of neuronal circuits. Some data show that NMDA receptors are a crucial class of receptors in the process of learning and memory. Studies have shown that excessive activation of NMDA receptors is closely related to the onset and progression of neurodegenerative diseases and mental illnesses. It is considered to be a key target for the treatment of such neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, stroke, amyotrophic lateral sclerosis, etc.) and mental illnesses (such as depression, NMDA encephalitis, epilepsy, schizophrenia, etc.). AMPA receptors mediate rapid excitatory synaptic transmitter transmission in the central nervous system. Drugs targeting AMPA receptors are mainly used for neuropsychiatric diseases (ischemic stroke, drug addiction, Alzheimer's disease, multiple sclerosis, epilepsy, and major depression, etc.). The occurrence of these diseases is closely related to the abnormal number or function of AMPA receptors. As the important physiological regulatory role of NMDA and AMPA receptors in synaptic plasticity and neuronal apoptosis has been verified and widely accepted by the academic community, NMDA and AMPA have also become one of the key targets for global CNS drug innovation. Multinational drug research and development institutions, including the first stage, have carried out drug research on this target, proving the feasibility of neuroprotectants targeting NMDA and AMPA in the treatment of neuropsychiatric diseases and broad commercial development prospects.

[0005] Bis(THF) lignans are a class of natural products widely distributed in plants, and are commonly found in traditional Chinese medicines such as Eucommia ulmoides, Acanthopanax senticosus, and Forsythia suspensa. Bis(THF) lignans have a variety of biological activities, mainly including antioxidant, anti-inflammatory, and anti-tumor activities, and are one of the hot natural products that have attracted much attention. However, because they have multiple chiral centers (usually 4) and the conformation of the bi(THF) ring substituted with two phenyl groups is complex and changeable. Therefore, it is difficult to synthesize these antioxidant active compounds. So far, few active compounds can be synthesized in large quantities. Skeleton hopping is a new drug development strategy for discovering novel structures with the same or similar pharmacological activities. The skeleton hopping method usually starts with a known active compound and obtains a novel active compound structure by changing the core skeleton of the molecule. Summary of the invention

[0006] The purpose of the present invention is to provide a 1,4-disubstituted piperazine-2,5-dione derivative, a preparation method and an application thereof. The present invention adopts a skeleton transition strategy to design and synthesize a series of 1,4-disubstituted piperazine-2,5-dione compounds as derivatives of ditetrahydrofuran lignans, and uses H2O2-induced oxidative stress model and NMDA-induced excitotoxic injury model to evaluate the pro-survival, antioxidant activity and anti-excitotoxic injury activity of the derivative.

[0007] The technical solution of the present invention:

[0008] A 1,4-disubstituted piperazine-2,5-dione derivative, the chemical structure of which is shown in Formula I:

[0009]

[0010] The aforementioned 1,4-disubstituted piperazine-2,5-dione derivative, wherein R1 is: 3,5-dimethoxyphenyl, 3,4-methylenedioxyphenyl, phenyl, 3-methoxyphenyl or 4-methoxyphenyl;

[0011] The R2 is: p-methoxyphenyl, p-methylphenyl, phenyl, p-fluorophenyl, p-trifluoromethylphenyl, p-tert-butylphenyl, methyl, m-bromophenyl, ethyl, propyl, 3,5-difluorophenyl, tert-butyl, cyclopropyl, methoxy or cyclopentylethyl.

[0012] The preparation method of the aforementioned 1,4-disubstituted piperazine-2,5-dione derivative has the following chemical reaction formula:

[0013]

[0014] The reaction conditions are as follows: (a) ethyl bromoacetate, potassium carbonate, anhydrous acetone, 60°C; (b) chloroacetyl chloride, dichloromethane / water, potassium carbonate, tetrabutylammonium hydrogen sulfate, room temperature; (c) sodium azide, N,N-dimethylformamide, 90°C; (d) triphenylphosphine, tetrahydrofuran, water, room temperature; (e) acyl chloride (8), 4-dimethylaminopyridine, dichloromethane, 0°C, room temperature;

[0015] The preparation method comprises the following steps:

[0016] (3) Using 1a-e and ethyl bromoacetate as raw materials and acetone as solvent, intermediates 2a-e were prepared;

[0017]

[0018] (4) Using the intermediate 2a-e obtained in step (1) and chloroacetyl chloride as raw materials, tetrabutylammonium hydrogen sulfate as a catalyst, and dichloromethane and water as solvents, intermediate 3a-e is prepared;

[0019]

[0020] (3) Using the intermediate 3a-e prepared in step (2) and sodium azide as raw materials and N,N-dimethylformamide as solvent, intermediate 4a-e was prepared;

[0021]

[0022] (4) Using the intermediate 4a-e obtained in step (3) and triphenylphosphine as raw materials, tetrahydrofuran and water as solvents, to prepare intermediate 7a-e;

[0023]

[0024] (5) Using the intermediate 4a-e obtained in step (4) and different acid chlorides (8) as raw materials, triethylamine as an acid binding agent, 4-dimethylaminopyridine as a catalyst, and dichloromethane as a solvent, the target compounds 9a-s are prepared;

[0025]

[0026] The method for preparing the aforementioned 1,4-disubstituted piperazine-2,5-dione derivatives, wherein in step (1): the aromatic amine compound 1a in the aromatic amine compounds 1a-e is 3,5-dimethoxyaniline, the aromatic amine compound 1b is 3,4-methylenedioxyaniline, the aromatic amine compound 1c is aniline, the aromatic amine compound 1d is 3-methoxyaniline, and the aromatic amine compound 1e is 4-methoxyaniline; wherein the molar ratio of the aromatic amine compounds 1a-e, anhydrous potassium carbonate and ethyl bromoacetate is 1:1.5:1.3;

[0027]

[0028] In the aforementioned method for preparing 1,4-disubstituted piperazine-2,5-dione derivatives, in step (2), the molar ratio of chloroacetyl chloride, intermediate compound 2a-e, anhydrous potassium carbonate and tetrabutylammonium hydrogen sulfate is 1.5:1:1.5:0.1.

[0029] In the aforementioned method for preparing 1,4-disubstituted piperazine-2,5-dione derivatives, in step (3), the molar ratio of sodium azide to amide compound 3a-e is 2.5:1.

[0030] The method for preparing the aforementioned 1,4-disubstituted piperazine-2,5-dione derivatives, in the step (4): the molar ratio of the azide compound 4a-e to triphenylphosphine is 1:1.5.

[0031] The method for preparing the aforementioned 1,4-disubstituted piperazine-2,5-dione derivatives, in the step (5): the chloride is the acyl chloride (8), the molar ratio of the intermediate compound 7a-e, 4-dimethylaminopyridine and triethylamine is 1.3:1:0.1:2.

[0032] In the above-mentioned method for preparing 1,4-disubstituted piperazine-2,5-dione derivatives, the acid chloride (8) is one of the following compounds:

[0033]

[0034] The invention discloses a use of a 1,4-disubstituted piperazine-2,5-dione derivative, wherein the derivative has the activities of promoting cell survival, anti-oxidation and inhibiting NMDA-induced excitatory damage.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] Based on the skeleton transition strategy, the present invention designs and synthesizes a series of 1,4-disubstituted piperazine-2,5-dione compounds as ditetrahydrofuran lignan derivatives, and uses the H2O2-induced oxidative stress model and the NMDA-induced excitotoxicity injury model to evaluate the antioxidant, pro-survival and anti-excitotoxicity activities of the derivatives, and determines that compounds 9a-9s all have pro-survival, antioxidant and anti-excitotoxicity activities, and further clarifies that the best representative compound 9r exerts pro-survival and antioxidant activities through the IL-6 / Nrf2 positive feedback signaling pathway (the effect of compounds 9a-9s on H2O2-induced SH-SY5Y cell oxidative damage reaches 75.78). In addition to being able to exert pro-survival and antioxidant activities by activating the IL-6 / Nrf2 positive feedback signaling pathway, the representative compound 9c can also inhibit NMDA-induced excitotoxicity by inhibiting the NMDA subunit NR2B and upregulating the protein level of AMPA, and finally exerts neuroprotective activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Attached Figure 1 .Design ideas for 1,4-disubstituted piperazine-2,5-dione compounds.

[0038] Attached Figure 2 .Under an inverted microscope, it was observed that the representative compound 9r with the best antioxidant activity significantly inhibited the death of SH-SY5Y cells induced by H2O2.

[0039] Attached Figure 3 . Flow cytometry detection showed that the representative compound 9r with the best antioxidant activity inhibited the apoptosis of SH-SY5Y cells induced by H2O2 after pretreatment.

[0040] Attached Figure 4.The immunoblotting method was used to investigate whether the representative compound 9r with the best antioxidant activity inhibited the apoptosis of SH-SY5Y cells induced by H2O2 by reducing the expression of pro-apoptosis related proteins (p53, Cl-PARP and Bax) and upregulating the expression of apoptosis inhibitory protein Bcl-2.

[0041] Attached Figure 5 The representative compound 9r with the best antioxidant activity inhibited the production of ROS in SH-SY5Y cells induced by H2O2. (A) The changes in the level of ROS in SH-SY5Y cells were observed under a fluorescence microscope. (B) The effect of the representative compound 9r on the level of ROS in SH-SY5Y cells induced by H2O2 was detected by flow cytometry. (C) Quantitative graph of ROS levels in SH-SY5Y cells.

[0042] Attached Figure 6 Representative compound 9r on the generation of mitochondrial membrane potential in H2O2-treated SH-SY5Y cells. (A) Changes in mitochondrial membrane potential in SH-SY5Y cells were observed under a fluorescence microscope. (B) Flow cytometry was used to detect the effects of representative compound 9r on mitochondrial membrane potential in H2O2-induced SH-SY5Y cells. (C) Quantification of JC-1 levels in SH-SY5Y cells.

[0043] Attached Figure 7 .The representative compound 9r promoted the survival of SH-SY5Y cells that were not damaged by H2O2 by activating the IL-6 pro-survival signaling pathway and upregulating the expression levels of pro-survival proteins (IL-6, p-Stat3 and p-Src).

[0044] Attached Figure 8 The representative compound 9r with the best antioxidant activity exerts its antioxidant activity by activating the Nrf2 antioxidant pathway, promoting the nuclear translocation of the antioxidant Nrf2, and increasing the expression level of the downstream antioxidant protein HO-1.

[0045] Attached Fig. 9 .Under an inverted microscope, it was observed that the representative compound 9c with the best anti-excitotoxic activity inhibited the death of SH-SY5Y cells induced by NMDA.

[0046] Attached Fig.10 .Flow cytometry was used to detect the effect of pretreatment with representative compound 9c on apoptosis of SH-SY5Y cells injured by NMDA.

[0047] Attached Fig.11 Immunoblotting was used to investigate whether the representative compound 9c with the best antioxidant activity inhibited the apoptosis of SH-SY5Y cells induced by H2O2 by reducing the expression of pro-apoptotic related proteins (p53 and Cl-PARP).

[0048] Attached Fig.12 .The representative compound 9c with the best anti-excitatory injury activity inhibited NMDA-induced excitatory injury in SH-SY5Y cells by reducing the protein level of NR2B and increasing the expression levels of AMPA and downstream p-mTOR.

[0049] Attached Fig.13 The representative compound 9c with the best anti-excitotoxic activity alleviated the damage of NMDA to SH-SY5Y cells and promoted the survival of SH-SY5Y cells by activating the IL-6 pro-survival pathway and the Nrf2 antioxidant pathway. DETAILED DESCRIPTION

[0050] Example 1: Preparation of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a), comprising the following steps:

[0051] (1) Preparation of ethyl 2-[(3,5-dimethoxyphenyl)amino]acetate (2a):

[0052] Under N2 protection, anhydrous potassium carbonate (135 mg, 0.977 mmol) was added to a solution of 1a (3,5-dimethoxyaniline) (100 mg, 0.653 mmol) in anhydrous acetone (5 mL), heated to 60 ° C and stirred for 1 h. Then ethyl bromoacetate (142 mg, 0.850 mmol) in anhydrous acetone (1 mL) was added dropwise to the mixture, and the mixture was stirred at 60 ° C for 8 hours (TLC monitoring). Potassium carbonate was filtered out and the solvent was removed under vacuum. Purification by silica gel column chromatography, eluent: PE (petroleum ether): EA (ethyl acetate) = 30: 1) to obtain yellow oily 2-[(3,5-dimethoxyphenyl) amino] ethyl acetate (2a) (134 mg, 0.561 mmol, yield 86%). Detection ESI-MS: m / z 240.1 [M+H] + .

[0053] (2) Preparation of ethyl N-(2-chloroacetyl)-N-[(3,5-dimethoxyphenyl)amino]acetate (3a):

[0054] At room temperature, chloroacetyl chloride (106 mg, 0.939 mmol) was added to a dichloromethane solution (6 mL) of ethyl 2-[(3,5-dimethoxyphenyl)amino]acetate (2a) (150 mg, 0.627 mmol) and tetrabutylammonium hydrogen sulfate (21 mg, 0.063 mmol) obtained in step (1). A solution of potassium carbonate (130 mg, 0.941 mmol) in water (2 mL) was slowly added dropwise to the mixture. The mixture was stirred (TLC was used to monitor the reaction). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (eluent: PE:EA=4:1) to obtain ethyl N-(2-chloroacetyl)-N-[(3,5-dimethoxyphenyl)amino]acetate (3a) as a yellow oil (194 mg, 0.614 mmol, 98% yield). ESI-MS: m / z 316.2, 318.2 [M+H] + .

[0055] (3) Preparation of ethyl (2-azidoacetyl)-N-[(3,5-dimethoxyphenyl)amino]acetate (4a):

[0056] Sodium azide (26 mg, 0.400 mmol) was added to a solution of ethyl N-(2-chloroacetyl)-N-[(3,5-dimethoxyphenyl)amino]acetate (3a) (50 mg, 0.158 mmol) obtained in step (2) in N,N-dimethylformamide (3 mL). The mixture was heated at 90°C for 1 hour (monitored by TLC for completion). Water (5 mL) was added to the mixture. N,N-dimethylformamide and water were evaporated at 90°C. The crude product was subjected to silica gel column chromatography (eluent: PE:EA=2:1) ​​to give ethyl N-(2-azidoacetyl)-N-[(3,5-dimethoxyphenyl)amino]acetate as a colorless oil (4a) (50 mg, 0.155 mmol, 98% yield). ESI-MS: m / z 323.3 [M+H] + .

[0057] (4) Preparation of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a):

[0058] Triphenylphosphine (61 mg, 0.232 mmol) was added to a solution of N-(2-azidoacetyl)-N-[(3,5-dimethoxyphenyl)amino]ethyl acetate (4a) (50 mg, 0.155 mmol) obtained in step (3) in tetrahydrofuran (5 mL), and water (0.5 mL) was added to the mixture. The mixture was stirred at room temperature for 4 hours (completeness monitored by TLC). Tetrahydrofuran was completely evaporated and the product was purified by silica gel column chromatography using ethyl acetate as eluent to give 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) as a white solid (23 mg, 0.092 mmol, yield 59%). ESI-MS: m / z 251.2 [M+H] + .

[0059] Example 2: Preparation of 1-(3,4-methylenedioxyphenyl)piperazine-2,5-dione (7b), comprising the following steps:

[0060] (1) Preparation of ethyl 2-[(3,4-methylenedioxyphenyl)amino]acetate (2b):

[0061] Under N2 protection, anhydrous potassium carbonate (756 mg, 5.469 mmol) was added to a solution of 1b (3,4-methylenedioxyaniline) (500 mg, 3.646 mmol) in anhydrous acetone (40 mL), heated to 60 ° C and stirred for 1 h. Then ethyl bromoacetate (791 mg, 4.740 mmol) in anhydrous acetone (1 mL) was added dropwise to the mixture, and the mixture was stirred at 60 ° C for 8 hours (TLC monitoring). Potassium carbonate was filtered out and the solvent was removed under vacuum. Purification by silica gel column chromatography, eluent: PE (petroleum ether): EA (ethyl acetate) = 15: 1) to obtain yellow oily 2-[(3,4-methylenedioxyphenyl) amino] ethyl acetate (2b) (716 mg, 3.208 mmol, yield 88%). Detection ESI-MS: m / z 224.25 [M+H] + .

[0062] (2) Preparation of ethyl N-(2-chloroacetyl)-N-[(3,4-methylenedioxyphenyl)amino]acetate (3b):

[0063] At room temperature, chloroacetyl chloride (379 mg, 3.360 mmol) was added to a dichloromethane solution (40 mL) of ethyl 2-[(3,4-methylenedioxyphenyl)amino]acetate (2b) (500 mg, 2.240 mmol) and tetrabutylammonium hydrogen sulfate (76 mg, 0.224 mmol) obtained in step (1). A solution of potassium carbonate (464 mg, 3.360 mmol) in water (12 mL) was slowly added dropwise to the mixture. The mixture was stirred (TLC was used to monitor the reaction). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (eluent: PE:EA=6:1) to obtain ethyl N-(2-chloroacetyl)-N-[(3,4-methylenedioxyphenyl)amino]acetate (3b) as a yellow oil (665 mg, 2.218 mmol, 99% yield). ESI-MS: m / z 300.68 [M+H] + .

[0064] (3) Preparation of ethyl (2-azidoacetyl)-N-[(3,4-methylenedioxyphenyl)amino]acetate (4b):

[0065] Sodium azide (271 mg, 4.170 mmol) was added to a solution of ethyl N-(2-chloroacetyl)-N-[(3,4-methylenedioxyphenyl)amino]acetate (3b) (500 mg, 1.668 mmol) obtained in step (2) in N,N-dimethylformamide (30 mL). The mixture was heated at 90°C for 1 hour (monitored by TLC for completion). Water (30 mL) was added to the mixture. N,N-dimethylformamide and water were evaporated at 90°C. The crude product was subjected to silica gel column chromatography (eluent: PE:EA=6:1) to give ethyl (2-azidoacetyl)-N-[(3,4-methylenedioxyphenyl)amino]acetate (4b) (490 mg, 1.60 mmol, 96% yield) as a colorless oil. ESI-MS: m / z 307.26 [M+H] + .

[0066] (4) Preparation of 1-(3,4-methylenedioxyphenyl)piperazine-2,5-dione (7b):

[0067] Triphenylphosphine (514 mg, 1.959 mmol) was added to a solution of (2-azidoacetyl)-N-[(3,4-methylenedioxyphenyl)amino]ethyl acetate (4b) (400 mg, 1.306 mmol) obtained in step (3) in tetrahydrofuran (25 mL), and water (2 mL) was added to the mixture. The mixture was stirred at room temperature for 4 hours (completeness was monitored by TLC). Tetrahydrofuran was completely evaporated and the product was purified by silica gel column chromatography using ethyl acetate as eluent to give 1-(3,4-methylenedioxyphenyl)piperazine-2,5-dione (7b) as a white solid (190 mg, 0.810 mmol, yield 62%). ESI-MS: m / z 235.19 [M+H] + .

[0068] Example 3: Preparation of 1-phenylpiperazine-2,5-dione (7c), comprising the following steps:

[0069] (1) Preparation of phenylglycine ethyl ester (2c):

[0070] Under N2 protection, anhydrous potassium carbonate (223 mg, 1.611 mmol) was added to a solution of 1c (aniline) (100 mg, 1.074 mmol) in anhydrous acetone (10 mL), heated to 60 ° C and stirred for 1 h. Then ethyl bromoacetate (233 mg, 1.396 mmol) in anhydrous acetone (2 mL) was added dropwise to the mixture, and the mixture was stirred at 60 ° C for 8 hours (TLC monitoring). Potassium carbonate was filtered out and the solvent was removed under vacuum. Purification by silica gel column chromatography, eluent: PE (petroleum ether): EA (ethyl acetate) = 20: 1) to obtain yellow oily phenylglycine ethyl ester (2c) (158 mg, 0.881 mmol, yield 82%). Detection ESI-MS: m / z 180.21 [M+H] + .

[0071] (2) Preparation of N-(2-chloroacetyl)-N-phenylglycine ethyl ester (3c):

[0072] At room temperature, chloroacetyl chloride (143 mg, 1.256 mmol) was added to a dichloromethane solution (8 mL) of phenylglycine ethyl ester (2c) (150 mg, 0.837 mmol) and tetrabutylammonium hydrogen sulfate (29 mg, 0.084 mmol) obtained in step (1). A solution of potassium carbonate (174 mg, 1.256 mmol) in water (3 mL) was slowly added dropwise to the mixture. The mixture was stirred (TLC monitored the reaction). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (eluent: PE:EA=6:1) to obtain yellow oil N-(2-chloroacetyl)-N-phenylglycine ethyl ester (3c) as a yellow oil (201 mg, 0.787 mmol, 94% yield). ESI-MS: m / z 256.67 [M+H] + .

[0073] (3) Preparation of N-(2-azidoacetyl)-N-phenylglycine ethyl ester (4c):

[0074] Sodium azide (95 mg, 1.466 mmol) was added to a solution of N-(2-chloroacetyl)-N-phenylglycine ethyl ester (3c) (150 mg, 0.587 mmol) obtained in step (2) in N,N-dimethylformamide (8 mL). The mixture was heated at 90°C for 1 hour (monitored by TLC for completion). Water (8 mL) was added to the mixture. N,N-dimethylformamide and water were evaporated at 90°C. The crude product was chromatographed on a silica gel column (eluent: PE:EA=5:1) to give N-(2-azidoacetyl)-N-phenylglycine ethyl ester (4c) as a colorless oil (146 mg, 0.558 mmol, 95% yield). ESI-MS: m / z 263.20 [M+H] + .

[0075] (4) Preparation of 1-phenylpiperazine-2,5-dione (7c):

[0076] Triphenylphosphine (150 mg, 0.572 mmol) was added to a solution of N-(2-azidoacetyl)-N-phenylglycine ethyl ester (4c) (100 mg, 0.381 mmol) obtained in step (3) in tetrahydrofuran (8 mL), and water (1 mL) was added to the mixture. The mixture was stirred at room temperature for 4 hours (completeness monitored by TLC). Tetrahydrofuran was completely evaporated and the product was purified by silica gel column chromatography using ethyl acetate as eluent to give 1-phenylpiperazine-2,5-dione (7c) as a white solid (42 mg, 0.221 mmol, yield 58%). ESI-MS: m / z 191.2 [M+H] + .

[0077] Example 4: Preparation of 1-(3-methoxyphenyl)piperazine-2,5-dione (7d), comprising the following steps:

[0078] (1) Preparation of (3-methoxyphenyl)glycine ethyl ester (2d):

[0079] Under N2 protection, anhydrous potassium carbonate (505 mg, 3.654 mmol) was added to a solution of 1d (3-methoxyaniline) (300 mg, 2.436 mmol) in anhydrous acetone (20 mL), heated to 60 ° C and stirred for 1 h. Then ethyl bromoacetate (529 mg, 3.167 mmol) in anhydrous acetone (5 mL) was added dropwise to the mixture, and the mixture was stirred at 60 ° C for 8 hours (TLC monitoring). Potassium carbonate was filtered out and the solvent was removed under vacuum. Purification by silica gel column chromatography, eluent: PE (petroleum ether): EA (ethyl acetate) = 10: 1) to obtain yellow oily (3-methoxyphenyl) glycine ethyl ester (2d) (431 mg, 2.071 mmol, yield 85%). Detection ESI-MS: m / z 209.18 [M+H] + .

[0080] (2) Preparation of N-(2-chloroacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (3d):

[0081] At room temperature, chloroacetyl chloride (244 mg, 2.160 mmol) was added to a dichloromethane solution (30 mL) of (3-methoxyphenyl)glycine ethyl ester (2d) (300 mg, 1.440 mmol) and tetrabutylammonium hydrogen sulfate (39 mg, 0.114 mmol) obtained in step (1). A solution of potassium carbonate (299 mg, 2.160 mmol) in water (10 mL) was slowly added dropwise to the mixture. The mixture was stirred (TLC was used to monitor the reaction). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (eluent: PE:EA=4:1) to obtain N-(2-chloroacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (3d) as a yellow oil (399 mg, 1.400 mmol, 97% yield). ESI-MS: m / z 286.74 [M+H] + .

[0082] (3) Preparation of N-(2-azidoacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (4d):

[0083] Sodium azide (171 mg, 2.625 mmol) was added to a solution of N-(2-chloroacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (3d) (300 mg, 1.050 mmol) obtained in step (2) in N,N-dimethylformamide (15 mL). The mixture was heated at 90°C for 1 hour (monitored by TLC for completion). Water (15 mL) was added to the mixture. N,N-dimethylformamide and water were evaporated at 90°C. The crude product was chromatographed on a silica gel column (eluent: PE:EA=2:1) ​​to give N-(2-azidoacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (4d) as a colorless oil (262 mg, 0.895 mmol, 94% yield). ESI-MS: m / z 293.30 [M+H] + .

[0084] (4) Preparation of 1-(3-methoxyphenyl)piperazine-2,5-dione (7d):

[0085] Triphenylphosphine (336 mg, 1.282 mmol) was added to a solution of N-(2-azidoacetyl)-N-(3-methoxyphenyl)glycine ethyl ester (4d) (250 mg, 0.855 mmol) obtained in step (3) in tetrahydrofuran (20 mL), and water (3 mL) was added to the mixture. The mixture was stirred at room temperature for 4 hours (completeness monitored by TLC). Tetrahydrofuran was completely evaporated and the product was purified by silica gel column chromatography using ethyl acetate as eluent to give 1-(3-methoxyphenyl)piperazine-2,5-dione (7d) as a white solid (119 mg, 0.539 mmol, yield 63%). ESI-MS: m / z 221.20 [M+H] + .

[0086] Example 5: Preparation of 1-(4-methoxyphenyl)piperazine-2,5-dione (7e), comprising the following steps:

[0087] (1) Preparation of (4-methoxyphenyl)glycine ethyl ester (2e):

[0088] Under N2 protection, anhydrous potassium carbonate (505 mg, 3.654 mmol) was added to a solution of 1e (4-methoxyaniline) (300 mg, 2.436 mmol) in anhydrous acetone (20 mL), heated to 60 ° C and stirred for 1 h. Then ethyl bromoacetate (529 mg, 3.167 mmol) in anhydrous acetone (5 mL) was added dropwise to the mixture, and the mixture was stirred at 60 ° C for 8 hours (TLC monitoring). Potassium carbonate was filtered out and the solvent was removed under vacuum. Purification by silica gel column chromatography, eluent: PE (petroleum ether): EA (ethyl acetate) = 10: 1) to obtain yellow oily (4-methoxyphenyl) glycine ethyl ester (2e) (446 mg, 2.144 mmol, yield 88%). Detection ESI-MS: m / z 209.20 [M+H] + .

[0089] (2) Preparation of N-(2-chloroacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (3e):

[0090] At room temperature, chloroacetyl chloride (244 mg, 2.160 mmol) was added to a dichloromethane solution (30 mL) of (4-methoxyphenyl)glycine ethyl ester (2e) (300 mg, 1.440 mmol) and tetrabutylammonium hydrogen sulfate (39 mg, 0.114 mmol) obtained in step (1). A solution of potassium carbonate (299 mg, 2.160 mmol) in water (10 mL) was slowly added dropwise to the mixture. The mixture was stirred (TLC was used to monitor the reaction). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (eluent: PE:EA=4:1) to obtain N-(2-chloroacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (3e) as a yellow oil (383 mg, 1.339 mmol, 93% yield). ESI-MS: m / z 286.76 [M+H] + .

[0091] (3) Preparation of N-(2-azidoacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (4e):

[0092] Sodium azide (171 mg, 2.625 mmol) was added to a solution of N-(2-chloroacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (3e) (300 mg, 1.050 mmol) obtained in step (2) in N,N-dimethylformamide (15 mL). The mixture was heated at 90°C for 1 hour (monitored by TLC for completion). Water (15 mL) was added to the mixture. N,N-dimethylformamide and water were evaporated at 90°C. The crude product was chromatographed on a silica gel column (eluent: PE:EA=2:1) ​​to give N-(2-azidoacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (4e) as a colorless oil (297 mg, 1.018 mmol, 97% yield). ESI-MS: m / z 293.34 [M+H] + .

[0093] (4) Preparation of 1-(4-methoxyphenyl)piperazine-2,5-dione (7e):

[0094] Triphenylphosphine (336 mg, 1.282 mmol) was added to a solution of N-(2-azidoacetyl)-N-(4-methoxyphenyl)glycine ethyl ester (4e) (250 mg, 0.855 mmol) obtained in step (3) in tetrahydrofuran (20 mL), and water (3 mL) was added to the mixture. The mixture was stirred at room temperature for 4 hours (completeness was monitored by TLC). Tetrahydrofuran was completely evaporated and the product was purified by silica gel column chromatography using ethyl acetate as eluent to give 1-(4-methoxyphenyl)piperazine-2,5-dione (7e) as a white solid (115 mg, 0.522 mmol, yield 61%). ESI-MS: m / z 221.18 [M+H] + .

[0095] Example 6: Preparation of 1-(3,5-dimethoxyphenyl)-4-(4-methoxybenzoyl)piperazine-2,5-dione (9a):

[0096] 4-Methoxybenzoyl chloride (53 mg, 0.312 mmol) in dichloromethane (1 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (60 mg, 0.240 mmol), triethylamine (48 mg, 0.474 mmol) and 4-dimethylaminopyridine (3 mg, 0.024 mmol) in dichloromethane (5 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as the eluent to give 1-(3,5-dimethoxyphenyl)-4-(4-methoxybenzoyl)piperazine-2,5-dione (9a) as a white solid (74 mg, 0.193 mmol, yield 80%), melting point 180-183°C, HRMS (ESI): [M+H] + 385.13763; [M+Na] + 407.12033.

[0097] Example 7: Preparation of 1-(3,5-dimethoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9b):

[0098] 4-Methylbenzoyl chloride (48 mg, 0.312 mmol) in dichloromethane (1 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (60 mg, 0.240 mmol), triethylamine (48 mg, 0.474 mmol) and 4-dimethylaminopyridine (3 mg, 0.024 mmol) in dichloromethane (5 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as the eluent to give 1-(3,5-dimethoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9b) as a white solid (72 mg, 0.197 mmol, yield 82%), melting point 131-134 °C, HRMS (ESI): [M+H] + 369.14343; [M+Na] + 391.12540.

[0099] Example 8: Preparation of 1-(3,4-methylenedioxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9c):

[0100] 4-Methylbenzoyl chloride (86 mg, 0.555 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,4-methylenedioxyphenyl)piperazine-2,5-dione (7b) (100 mg, 0.427 mmol), triethylamine (86 mg, 0.854 mmol) and 4-dimethylaminopyridine (5 mg, 0.043 mmol) in dichloromethane (10 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,4-methylenedioxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9c) as a white solid (133 mg, 0.376 mmol, yield 88%), melting point 174-177 ° C, HRMS (ESI): [M+H] + 353.11182; [M+Na] + 375.09427.

[0101] Example 9: Preparation of 1-(4-methylbenzoyl)-4-phenylpiperazine-2,5-dione (9d):

[0102] 4-Methylbenzoyl chloride (106 mg, 0.684 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-phenylpiperazine-2,5-dione (7c) (100 mg, 0.526 mmol), triethylamine (106 mg, 1.052 mmol) and 4-dimethylaminopyridine (6 mg, 0.053 mmol) in dichloromethane (10 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as the eluent to give 1-(4-methylbenzoyl)-4-phenylpiperazine-2,5-dione (9d) as a white solid (144 mg, 0.468 mmol, yield 89%), melting point 170-173 ° C, HRMS (ESI): [M+Na] + 3331.10440.

[0103] Example 10: Preparation of 1-(3-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9e):

[0104] 4-Methylbenzoyl chloride (91 mg, 0.590 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3-methoxyphenyl)piperazine-2,5-dione (7d) (100 mg, 0.454 mmol), triethylamine (92 mg, 0.908 mmol) and 4-dimethylaminopyridine (5 mg, 0.045 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was purified by silica gel column chromatography using PE:EA=2:1 as eluent to give 1-(3-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9e) as a white solid (132 mg, 0.390 mmol, yield 86%), melting point 142-145 °C, HRMS (ESI): [M+H] + 339.13260; [M+Na] + 361.11490.

[0105] Example 11: Preparation of 1-(4-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9f):

[0106] 4-Methylbenzoyl chloride (91 mg, 0.590 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(4-methoxyphenyl)piperazine-2,5-dione (7e) (100 mg, 0.454 mmol), triethylamine (92 mg, 0.908 mmol) and 4-dimethylaminopyridine (5 mg, 0.045 mmol) in dichloromethane (10 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was purified by silica gel column chromatography using PE:EA=2:1 as eluent to give 1-(4-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9f) as a white solid (135 mg, 0.395 mmol, yield 87%), melting point 142-145 °C, HRMS (ESI): [M+H] + 339.13303; [M+Na] + 361.11481.

[0107] Example 12: Preparation of 1-(3,5-dimethoxyphenyl)-4-benzoylpiperazine-2,5-dione (9 g):

[0108] Benzoyl chloride (73 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine, extracted three times with dichloromethane (20 mL), the organic phases were combined, dried over anhydrous magnesium sulfate, the solvent was removed in vacuo, and the product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,5-dimethoxyphenyl)-4-benzoylpiperazine-2,5-dione (9 g) as a white solid (120 mg, 0.340 mmol, yield 85%), melting point 130-133 ° C, HRMS (ESI): [M+H] + 355.12750; [M+Na] + 377.10965.

[0109] Example 13: Preparation of 1-(3,5-dimethoxyphenyl)-4-(4-fluorobenzoyl)piperazine-2,5-dione (9h):

[0110] 4-Fluorobenzoyl chloride (82 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,5-dimethoxyphenyl)-4-(4-fluorobenzoyl)piperazine-2,5-dione (9h) as a white solid (131 mg, 0.352 mmol, yield 88%), melting point 149-152 °C, HRMS (ESI): [M+H] + 373.11835; [M+Na]+ 395.10043.

[0111] Example 14: Preparation of 1-(3,5-dimethoxyphenyl)-4-(4-(trifluoromethyl)benzoyl)piperazine-2,5-dione (9i):

[0112] 4-(Trifluoromethyl)benzoyl chloride (108 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give: 1-(3,5-dimethoxyphenyl)-4-(4-(trifluoromethyl)benzoyl)piperazine-2,5-dione (9i) as a white solid (132 mg, 0.312 mmol, yield 78%), melting point 141-144°C, HRMS (ESI): [M+H] + 423.11514; [M+Na] + 445.09738.

[0113] Example 15: Preparation of 1-(3,5-dimethoxyphenyl)-4-(4-(tert-butyl)benzoyl)piperazine-2,5-dione (9j):

[0114] 4-(tert-butyl)benzoyl chloride (102 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (10 mg, 0.040 mmol) in dichloromethane (5 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give: 1-(3,5-dimethoxyphenyl)-4-(4-(tert-butyl)benzoyl)piperazine-2,5-dione (9j) as a white solid (115 mg, 0.280 mmol, yield 70%), melting point 193-196°C, HRMS (ESI): [M+H] + 411.18982; [M+Na] + 433.17227.

[0115] Example 16: Preparation of 1-(3,5-dimethoxyphenyl)-4-acetylpiperazine-2,5-dione (9k):

[0116] Acetyl chloride (41 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine, extracted three times with dichloromethane (20 mL), the organic phases were combined, dried over anhydrous magnesium sulfate, the solvent was removed in vacuo, and the product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-dimethoxyphenyl)-4-acetylpiperazine-2,5-dione (9k) as a white solid (74 mg, 0.252 mmol, yield 63%), melting point 172-175°C, HRMS (ESI): [M+H] + 293.11212; [M+Na] + 315.09421.

[0117] Example 17: Preparation of 1-(3,5-dimethoxyphenyl)-4-(3-bromobenzoyl)piperazine-2,5-dione (91):

[0118] 3-Bromobenzoyl chloride (114 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,5-dimethoxyphenyl)-4-(3-bromobenzoyl)piperazine-2,5-dione (9l) as a white solid (152 mg, 0.352 mmol, yield 88%), melting point 192-195°C, HRMS (ESI): [M+H] + 433.03812.

[0119] Example 18: Preparation of 1-(3,5-dimethoxyphenyl)-4-propionylpiperazine-2,5-dione (9m):

[0120] Propionyl chloride (48 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine, extracted three times with dichloromethane (20 mL), the organic phases were combined, dried over anhydrous magnesium sulfate, the solvent was removed in vacuo, and the product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-dimethoxyphenyl)-4-propionylpiperazine-2,5-dione (9m) as a white solid (73 mg, 0.240 mmol, yield 60%), melting point 112-115°C, HRMS (ESI): [M+H] + 307.12772; [M+Na] + 329.10980.

[0121] Example 19: Preparation of 1-(3,5-dimethoxyphenyl)-4-butyrylpiperazine-2,5-dione (9n):

[0122] At 0°C, butyryl chloride (55 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine, extracted three times with dichloromethane (20 mL), the organic phases were combined, dried over anhydrous magnesium sulfate, the solvent was removed in vacuo, and the product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-dimethoxyphenyl)-4-butyrylpiperazine-2,5-dione (9n) as a white solid (83 mg, 0.260 mmol, yield 65%), melting point 136-139°C, HRMS (ESI): [M+H] + 321.14340; [M+Na] + 343.12558.

[0123] Example 20: Preparation of 1-(3,5-difluorobenzoyl)-4-(3,5-dimethoxyphenyl)piperazine-2,5-dione (9o):

[0124] 3,5-difluorobenzoyl chloride (92 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-difluorobenzoyl)-4-(3,5-dimethoxyphenyl)piperazine-2,5-dione (9o) as a white solid (128 mg, 0.328 mmol, yield 82%), melting point 182-185°C, HRMS (ESI): [M+H] + 391.10870; [M+Na] + 413.09103.

[0125] Example 21: Preparation of 1-(3,5-dimethoxyphenyl)-4-pivaloylpiperazine-2,5-dione (9p):

[0126] Pivaloyl chloride (63 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine, extracted three times with dichloromethane (20 mL), the organic phases were combined, dried over anhydrous magnesium sulfate, the solvent was removed in vacuo, and the product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-dimethoxyphenyl)-4-pivaloylpiperazine-2,5-dione (9p) as a white solid (100 mg, 0.300 mmol, yield 75%), melting point 180-183°C, HRMS (ESI): [M+H] + 335.15897; [M+Na] + 357.14112.

[0127] Example 22: Preparation of 1-(3,5-dimethoxyphenyl)-4-(cyclopropanecarbonyl)piperazine-2,5-dione (9q):

[0128] Cyclopropylcarbonyl chloride (54 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to obtain: 1-(3,5-dimethoxyphenyl)-4-(cyclopropanecarbonyl)piperazine-2,5-dione (9q) as a white solid (81 mg, 0.256 mmol, yield 64%), melting point 155-158°C, HRMS (ESI): [M+H] + 319.16762; [M+Na] + 341.10986.

[0129] Example 23: Preparation of 1-(3,5-dimethoxyphenyl)-4-(3-cyclopentylpropionyl)piperazine-2,5-dione (9r):

[0130] 3-Cyclopentylpropionyl chloride (84 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) at 0°C using a dropping funnel. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,5-dimethoxyphenyl)-4-(3-cyclopentylpropionyl)piperazine-2,5-dione (9r) as a white solid (132 mg, 0.352 mmol, yield 88%), melting point 141-144°C, HRMS (ESI): [M+H] + 375.18997; [M+Na] + 397.17230.

[0131] Example 24: Preparation of 1-(3,5-dimethoxyphenyl)-4-(2-methoxyacetyl)piperazine-2,5-dione (9s):

[0132] 2-Methoxyacetyl chloride (56 mg, 0.520 mmol) in dichloromethane (2 mL) was added dropwise to a solution of 1-(3,5-dimethoxyphenyl)piperazine-2,5-dione (7a) (100 mg, 0.400 mmol), triethylamine (81 mg, 0.800 mmol) and 4-dimethylaminopyridine (5 mg, 0.040 mmol) in dichloromethane (10 mL) using a dropping funnel at 0°C. The mixture was stirred at room temperature for 2 hours. The completion of the reaction was monitored by TLC. The mixture was poured into 20 mL of saturated brine and extracted three times with dichloromethane (20 mL). The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo. The product was chromatographed on a silica gel column using PE:EA=2:1 as an eluent to give 1-(3,5-dimethoxyphenyl)-4-(2-methoxyacetyl)piperazine-2,5-dione (9s) as a white solid (52 mg, 0.160 mmol, yield 40%), melting point 138-141 °C, HRMS (ESI): [M+H] + 323.12238; [M+Na]+ 345.10474.

[0133] Experimental example: Detection method research

[0134] 1 Experimental Materials

[0135] 1.1 Drug testing

[0136] Silica gel column eluent PE (petroleum ether): the full name of EA (ethyl acetate), DMF (N, N-dimethylformamide) and THF (tetrahydrofuran).

[0137] 1.2 Instruments

[0138] All reagents and solvents used in the experiment are commercially available and can be used without further purification. 1HNMR data were measured and recorded on a Bruker 600 MHz NMR spectrometer, and 13CNMR spectral data were measured and recorded on a Bruker 151 MHz NMR spectrometer, with chloroform-d as solvent and TMS as internal standard. HRMS of all target compounds were measured using electrospray ionization on a mass spectrometer (microTOF-Q, Bruker Inc). The melting point was measured on a melting point instrument (Shanghai Micro Melting Point Instrument), and the values ​​were uncorrected.

[0139] 2 Compound design

[0140] Based on the principle of skeleton transition and using SPARK drug design software, we took tetrahydrofuran lignin compounds with biological activity as lead compounds, replaced the furan lignan nucleus with biological electronic isosteres, and designed a series of 1,4-disubstituted piperazine-2,5-dione derivatives. The specific design scheme is as follows: Figure 1 shown.

[0141] 3 Preparation plan

[0142] The desired precursor 7a-e is synthesized from aromatic amine 1a-e. Compound 1a-e is reacted with ethyl bromoacetate via a nucleophilic substitution reaction to afford intermediate 2a-e. 2a-e is treated with chloroacetyl chloride under phase transfer catalysis to afford amide 3a-e. Compound 3a-e is then treated with excess sodium azide in DMF solution at 90°C to provide azide compound 4a-e in excellent yield. Subsequently, substrate 4a-e is subjected to an intramolecular aza-Wittig reaction. Intermediate 4a-e is treated with a solution of triphenylphosphine in THF at room temperature to afford compound 5a-e. Intermediate 6a-e is obtained from compound 5a-e via a spontaneous cyclization reaction. Next, intermediate 6a-e is stirred in wet THF (not anhydrous), resulting in cleavage and rearrangement of the enol ether to afford 7a-e. Finally, 7a-e is reacted with the corresponding chloride (8) to form target compound 9a-s.

[0143]

[0144]

[0145] Reaction conditions: (a) ethyl bromoacetate, potassium carbonate, anhydrous acetone, 60°C; (b) chloroacetyl chloride, dichloromethane / water, potassium carbonate, tetrabutylammonium hydrogen sulfate, room temperature; (c) sodium azide, N,N-dimethylformamide, 90°C; (d) triphenylphosphine, tetrahydrofuran, water, room temperature; (e) acyl chloride (8), 4-dimethylaminopyridine, dichloromethane, 0°C, room temperature.

[0146]

[0147] 5 Appearance, melting point, and NMR test results of compounds 9a-9s:

[0148] (1) The target product 1-(3,5-dimethoxyphenyl)-4-(4-methoxybenzoyl)piperazine-2,5-dione (9a) (74 mg, 0.193 mmol, yield 80%) in Example 6 was obtained as a white solid with a melting point of 180-183°C. 1 H NMR(600MHz,Chloroform-d)δ7.70(d,J=8.8Hz,2H),6.92(d,J=8.8Hz,2H),6.48(d,J= 2.2Hz,2H),6.42(t,J=2.2Hz,1H),4.54(s,2H),4.45(s,2H),3.86(s,3H),3.80(s,6H). 13 C NMR (151MHz, CDCl3) δ170.47,166.97,164.84,163.81,161.36,141.02,131.85 ,125.91,113.81,103.51,99.65,55.68,55.62,54.17,48.77.HRMS(ESI):calcd for C 20 H 21 O6N2[M+H] + m / z385.13941,found385.13763;C 20 H 20 O6N2Na[M+Na] + m / z407.12136,found407.12033.

[0149] (2) The target product 1-(3,5-dimethoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9b) in Example 7 was obtained as a white solid with a yield of 82% and a melting point of 131-134°C. 1 H NMR(600MHz,Chloroform-d)δ7.59(d,J=8.0Hz,2H),7.24(d,J=8.0Hz,2H),6.49(d,J= 2.2Hz,2H),6.43(t,J=2.2Hz,1H),4.57(s,2H),4.46(s,2H),3.81(s,6H),2.41(s,3H). 13 C NMR (151MHz, CDCl3) δ171.17,166.88,164.74,161.39,144.09,141.00,131.19 ,129.26,129.21,103.53,99.69,55.69,54.17,48.58,21.87.HRMS(ESI):calcd for C 20 H 21 O5N2[M+H] + m / z369.14450,found369.14343;C 20 H 20 O5N2Na[M+Na] + m / z391.12644,found391.12540.

[0150] (3) The target product 1-(3,4-methylenedioxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9c) in Example 8 was obtained as a white solid with a yield of 88% and a melting point of 174-177°C. 1 H NMR(600MHz,Chloroform-d)δ7.58(d,J=8.0Hz,2H),7.24(d,J=8.0Hz,2H),6.88–6.83( m,2H),6.74(dd,J=8.3,2.2Hz,1H),6.01(s,2H),4.55(s,2H),4.42(s,2H),2.41(s,3H). 13 C NMR (151MHz, CDCl3) δ171.20,166.86,164.93,148.42,147.19,144.07,133.21,131.20, 129.23,129.21,118.50,108.65,107.01,101.99,54.59,48.44,21.87.HRMS(ESI):calcd for C 19 H17 O5N2[M+H] + m / z353.11320,found353.11182;C 19 H 16 O5N2Na[M+Na] + m / z375.09514,found375.09427.

[0151] (4) The target product 1-(4-methylbenzoyl)-4-phenylpiperazine-2,5-dione (9d) in Example 9 was obtained as a white solid with a yield of 89% and a melting point of 170-173°C. 1 H NMR(600MHz,Chloroform-d)δ7.60(d,J=8.2Hz,2H),7.46(t,J=8.0Hz,2H),7. 37–7.31(m,3H),7.25(d,J=8.0Hz,2H),4.58(s,2H),4.49(s,2H),2.41(s,3H). 13 C NMR(151MHz, CDCl3)δ171.17,166.94,164.76,144.07,139.37,131.18,129.56,129.25,129.20,127.63,124.83,54.06,48.53,21.86.HRMS(ESI):calcdfor C 18 H 16 O3N2Na[M+Na] + m / z331.10531,found3331.10440.

[0152] (5) The target product 1-(3-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9e) in Example 10 was obtained as a white solid with a yield of 86% and a melting point of 142-145°C. 1 H NMR(600MHz,Chloroform-d)δ7.59(d,J=8.2Hz,2H),7.36(t,J=8.1Hz,1H),7.24(d,J=8.0Hz,2 H),6.93–6.89(m,2H),6.89–6.85(m,1H),4.57(s,2H),4.47(s,2H),3.83(s,3H),2.41(s,3H). 13C NMR (151MHz, CDCl3) δ171.16,166.91,164.73,160.40,144.06,140.46,131.18,130.28, 129.24,129.19,116.84,113.21,111.15,55.60,54.10,48.55,21.86.HRMS(ESI):calcd for C 19 H 19 O4N2[M+H] + m / z339.13393,found339.13260; C 19 H 18 O4N2Na[M+Na] + m / z361.11588,found361.11490.

[0153] (6) The target product 1-(4-methoxyphenyl)-4-(4-methylbenzoyl)piperazine-2,5-dione (9f) in Example 11 was obtained as a white solid with a yield of 87% and a melting point of 142-145°C. 1 H NMR (600MHz, Chloroform-d) δ7.59(d,J=8.2Hz,2H),7.31–7.18(m,4H),7.01–6.92(m,2H),4.56(s,2H),4.44(s,2H),3.83(s,3H),2.41(s,3H). 13 C NMR (151MHz, CDCl3) δ171.22,166.99,164.85,158.84,144.03,132.15,131.23,1 29.22,129.19,126.40,114.83,55.66,54.45,48.48,21.86.HRMS(ESI):calcdfor C 19 H 19 O4N2[M+H] + m / z339.13393,found339.13303;C 19 H 18 O4N2Na[M+Na] + m / z361.11588,found361.11481.

[0154] (7) The target product 1-(3,5-dimethoxyphenyl)-4-benzoylpiperazine-2,5-dione (9 g) in Example 12 was obtained as a white solid with a yield of 85% and a melting point of 130-133°C. 1H NMR(600MHz,Chloroform-d)δ7.70–7.65(m,2H),7.61–7.53(m,1H),7.45(t,J=7.8Hz,2 H), 6.49 (d, J = 2.2Hz, 2H), 6.43 (t, J = 2.2Hz, 1H), 4.59 (s, 2H), 4.47 (s, 2H), 3.81 (s, 6H). 13 C NMR (151MHz, CDCl3) δ171.28,166.82,164.65,161.41,140.97,134.16,133.01,128.94,128.48,103.56,99.73,55.70,54.17,48.47.HRMS(ESI):calcd for C 19 H 19 O5N2[M+H] + m / z355.12885,found355.12750; C 19 H 18 O5N2Na[M+Na] + m / z377.11079,found377.10965.

[0155] (8) The target product 1-(3,5-dimethoxyphenyl)-4-(4-fluorobenzoyl)piperazine-2,5-dione (9h) in Example 13 was obtained as a white solid with a yield of 88% and a melting point of 149-152°C. 1 H NMR(600MHz,Chloroform-d)δ7.74–7.68(m,2H),7.12(t,J=8.5Hz,2H),6.48( d,J=2.2Hz,2H),6.43(t,J=2.2Hz,1H),4.57(s,2H),4.47(s,2H),3.81(s,6H). 13 C NMR(151MHz,CDCl3)δ170.04,166.89,165.84(166.47,164.78,d, 1 J=254.9Hz),164.52,161.39,140.90,131.76(131.79,131.73,d, 3 J=9.3Hz),130.19(130.20,130.18,d, 4 J=3.1Hz,),115.74(115.82,115.67,d, 2 J=22.3Hz),103.53,99.65,55.69,54.15,48.55. 19F NMR(565MHz,CDCl3)δ-104.70.HRMS(ESI):calcdfor C 19 H 18 O5N2F[M+H] + m / z373.11943,found373.11835; C 19 H 17 O5N2FNa[M+Na] + m / z395.10137, found395.10043.

[0156] (9) The target product 1-(3,5-dimethoxyphenyl)-4-(4-(trifluoromethyl)benzoyl)piperazine-2,5-dione (9i) in Example 14 was obtained as a white solid with a yield of 78% and a melting point of 141-144°C. 1 H NMR(600MHz,Chloroform-d)δ7.74(d,J=8.2Hz,2H),7.71(d,J=8.2Hz,2H),6.48 (d,J=2.2Hz,2H),6.44(t,J=2.3Hz,1H),4.63(s,2H),4.48(s,2H),3.81(s,6H). 13 C NMR (151MHz, CDCl3) δ170.02,166.73,164.22,161.45,140.82,137.69,134.05(134.37,134.15,133.94,133.72,q, 2 J=32.9Hz),128.95,125.53(125.56,125.54,125.51,125.49,q, 3 J=3.8Hz),123.62(126.32,124.51,122.71,120.90,q, 1 J=273.0Hz),103.57,99.74,55.71,54.14,48.24. 19 FNMR(565MHz,CDCl3)δ-63.11.HRMS(ESI):calcd for C 20 H 18 O5N2F3[M+H] + m / z423.11623,found423.11514;C 20 H 17 O5N2F3Na[M+Na] + m / z445.0918, found445.09738.

[0157] (10) The target product 1-(3,5-dimethoxyphenyl)-4-(4-(tert-butyl)benzoyl)piperazine-2,5-dione (9j) in Example 15 was obtained as a white solid with a yield of 70% and a melting point of 193-196°C. 1 H NMR(600MHz,Chloroform-d)δ7.64(d,J=8.4Hz,2H),7.46(d,J=8.4Hz,2H),6.49(d,J= 2.0Hz,2H),6.43(t,J=2.1Hz,1H),4.57(s,2H),4.47(s,2H),3.81(s,6H),1.34(s,9H). 13 C NMR (151MHz, CDCl3) δ171.16,166.91,164.73,161.41,156.99,141.02,131.04,12 9.14,125.51,103.57,99.75,55.69,54.20,48.62,35.29,31.19.HRMS(ESI):calcd for C 23 H 27 O5N2[M+H] + m / z411.19145,found411.18982; C 23 H 26 O5N2Na[M+Na] + m / z433.17339,found433.17227.

[0158] (11) The target product 1-(3,5-dimethoxyphenyl)-4-acetylpiperazine-2,5-dione (9k) in Example 16 was obtained as a white solid with a yield of 63% and a melting point of 172-175°C. 1 H NMR (600MHz, Chloroform-d) δ6.42(d,J=2.2Hz,2H),6.40(t,J=2.2Hz,1H),4.56(s,2H),4.46(s,2H),3.78(s,6H),2.62(s,3H). 13 CNMR(151MHz, CDCl3)δ171.19,166.36,164.27,161.34,140.93,103.46,99.70,55.66,54.74,46.49,27.11.HRMS(ESI):calcd for C 14 H 17 O5N2[M+H] + m / z293.11320,found293.11212;C14 H 16 O5N2Na[M+Na] + m / z315.09514,found315.09421.

[0159] (12) The target product 1-(3,5-dimethoxyphenyl)-4-(3-bromobenzoyl)piperazine-2,5-dione (91) in Example 17 was obtained as a white solid with a yield of 88% and a melting point of 192-195°C. 1 H NMR(600MHz,Chloroform-d)δ7.78(s,1H),7.70–7.65(m,1H),7.59–7.54(m,1H),7.32(t,J=7. 9Hz, 1H), 6.48 (d, J = 2.2Hz, 2H), 6.43 (t, J = 2.2Hz, 1H), 4.58 (s, 2H), 4.47 (s, 2H), 3.80 (s, 6H). 13 C NMR (151MHz, CDCl3) δ169.78,166.70,164.31,161.41,140.86,136.15,135.71,131 .64,129.96,127.31,122.46,103.54,99.73,55.70,54.08,48.34.HRMS(ESI):calcd for C 19 H 18 O5N2Br[M+H] + m / z433.03936,found433.03812.

[0160] (13) The target product 1-(3,5-dimethoxyphenyl)-4-propionylpiperazine-2,5-dione (9m) in Example 18 was obtained as a white solid with a yield of 60% and a melting point of 112-115°C. 1 H NMR(600MHz,Chloroform-d)δ6.42(d,J=2.0Hz,2H),6.39(t,J=2.0Hz,1H),4.57 (s,2H),4.45(s,2H),3.78(s,6H),3.00(q,J=7.2Hz,2H),1.19(t,J=7.2Hz,3H). 13 C NMR (151MHz, CDCl3) δ175.24,166.24,164.41,161.33,140.94,103.43,99.66,55.65,54.85,46.65,32.81,8.77.HRMS(ESI):calcd forC 15 H 19O5N2[M+H] + m / z307.12885,found307.12772;C 15 H 18 O5N2Na[M+Na] + m / z329.11079,found329.10980.

[0161] (14) The target product 1-(3,5-dimethoxyphenyl)-4-butyrylpiperazine-2,5-dione (9n) in Example 19 was obtained as a white solid with a yield of 65% and a melting point of 136-139°C. 1 H NMR(600MHz,Chloroform-d)δ6.42(d,J=2.2Hz,2H),6.40–6.38(m,1H),4.56(s,2H),4.45 (s,2H),3.78(s,6H),2.95(t,J=7.4Hz,2H),1.71(q,J=7.4Hz,2H),0.99(t,J=7.4Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.31,166.25,164.43,161.33,140.94,103.43,99.66,55.65,54.86,46.57,41.04,17.95,13.78.HRMS(ESI):calcd for C 16 H 21 O5N2[M+H] + m / z321.14450,found321.14340; C 16 H 20 O5N2Na[M+Na] + m / z343.12644,found343.12558.

[0162] (15) The target product 1-(3,5-difluorobenzoyl)-4-(3,5-dimethoxyphenyl)piperazine-2,5-dione (9o) in Example 20 was obtained as a white solid with a yield of 82% and a melting point of 182-185°C. 1 H NMR(600MHz,Chloroform-d)δ7.19–7.15(m,1H),7.15–7.12(m,1H),7.00(tt,J=8.6,2.3Hz ,1H),6.47(d,J=2.2Hz,2H),6.43(t,J=2.2Hz,1H),4.58(s,2H),4.48(s,2H),3.81(s,6H). 13C NMR(151MHz,CDCl3)δ168.94(168.95,168.93,168.90,t, 4 J=3.3Hz),166.68,164.07,162.71(163.58,163.49,161.91,161.83,dd, 1 J=250.9,12.1Hz),161.45,140.78,137.31(137.37,137.30,137.24,t, 3 J=9.2Hz),111.83(111.91,111.87,111.76,111.72,dd, 2 J=21.4,5.9Hz),108.10(108.26,108.09,107.93,t, 2 J=25.2Hz),103.57,99.81,55.71,54.06,48.28. 19 FNMR(565MHz,CDCl3)δ-108.13.HRMS(ESI):calcd for C 19 H 17 O5N2F2[M+H] + m / z391.11000,found391.10870; C 19 H 16 O5N2F2Na[M+Na] + m / z413.09195, found413.09103.

[0163] (16) The target product 1-(3,5-dimethoxyphenyl)-4-pivaloylpiperazine-2,5-dione (9p) in Example 21 was obtained as a white solid with a yield of 75% and a melting point of 180-183°C. 1 H NMR (600MHz, Chloroform-d) δ6.44(d,J=2.2Hz,2H),6.41(t,J=2.2Hz,1H),4.42(s,2H),4.37(s,2H),3.79(s,6H),1.36(s,9H). 13 CNMR(151MHz, CDCl3)δ184.59,166.61,164.93,161.38,140.94,103.48,99.66,55.68,54.29,49.42,43.61,27.32.HRMS(ESI):calcd for C 17 H 23 O5N2[M+H] +m / z335.16015,found335.15897; C 17 H 22 O5N2Na[M+Na] + m / z357.14209,found357.14112.

[0164] (17) The target product 1-(3,5-dimethoxyphenyl)-4-(cyclopropanecarbonyl)piperazine-2,5-dione (9q) in Example 22 was obtained as a white solid with a yield of 64% and a melting point of 155-158°C. 1 H NMR(600MHz,Chloroform-d)δ6.44(d,J=2.2Hz,2H),6.40(t,J=2.2Hz,1H),4.53(s,2H),4. 49(s,2H),3.78(s,6H),2.99(tt,J=7.9,4.6Hz,1H),1.24–1.18(m,2H),1.10–1.03(m,2H). 13 C NMR(151MHz, CDCl3)δ175.84,166.95,164.49,161.33,140.97,103.44,99.68,55.66,54.90,47.14,16.14,11.91.HRMS(ESI):calcd for C 16 H 19 O5N2[M+H] + m / z319.12885,found319.16762;C 16 H 18 O5N2Na[M+Na] + m / z341.11079,found341.10986.

[0165] (18) The target product 1-(3,5-dimethoxyphenyl)-4-(3-cyclopentylpropionyl)piperazine-2,5-dione (9r) in Example 23 was obtained as a white solid with a yield of 88% and a melting point of 141-144°C. 1 H NMR(600MHz,Chloroform-d)δ6.42(d,J=2.2Hz,2H),6.39(t,J=2.2Hz,1H),4.55(s,2H),4.44(s,2H),3.78(s,6H), 3.01–2.95(m,2H),1.85–1.74(m,3H),1.72–1.65(m,2H),1.65–1.56(m,2H),1.54–1.48(m,2H),1.14–1.08(m,2H). 13C NMR (151MHz, CDCl3) δ174.64,166.21,164.44,161.31,140.93,103.42,99.63, 55.64,54.85,46.62,39.64,38.47,32.62,30.71,25.22.HRMS(ESI):calcdfor C 20 H 27 O5N2[M+H] + m / z375.19145,found375.18997; C 20 H 26 O5N2Na[M+Na] + m / z397.17339,found397.17230.

[0166] (19) The target product 1-(3,5-dimethoxyphenyl)-4-(2-methoxyacetyl)piperazine-2,5-dione (9s) in Example 24 was obtained as a white solid with a yield of 40% and a melting point of 138-141°C. 1 H NMR (600MHz, Chloroform-d) δ6.41(d,J=2.2Hz,2H),6.40(t,J=2.2Hz,1H),4.62(s,2H),4.60(s,2H),4.46(s,2H),3.78(s,6H),3.49(s,3H). 13 C NMR(151MHz, CDCl3)δ171.78,166.14,163.81,161.38,140.86,103.51,99.76,74.91,59.62,55.67,54.48,46.28.HRMS(ESI):calcd for C 15 H 19 O6N2[M+H] + m / z323.12376,found323.12238;C 15 H 18 O6N2Na[M+Na] + m / z345.10571,found345.10474.

[0167] 6 compounds on the viability of SH-SY5Y cells after H2O2 treatment

[0168] The inhibitory effect of the compounds on H2O2-induced oxidative damage and NMDA-induced excitotoxic damage was detected by tetrazolyl colorimetry. After SH-SY5Y cells were cultured in 96-well plates for 24 hours, the corresponding concentrations of compounds 9c and 9r were prepared in the culture medium, and the cells were pretreated for 2 hours. After removing the culture medium, SH-SY5Y cells were treated with 200μM H2O2 prepared in serum-free culture medium or 2mM NMDA prepared in magnesium-free extracellular solution (H2O2 treatment time was 2 hours, NMDA treatment time was 0.5 hours), and three replicates were set for each group. The treated cells were replaced with complete RPMI-1640 culture medium containing 10% fetal bovine serum and continued to be cultured for 24 hours. The viability of SH-SY5Y cells was detected by tetrazolyl colorimetry.

[0169] It can be seen from Table 1 that compounds 9a-9s can promote the proliferation and growth of SH-SY5Y cells to varying degrees within the range of 5μM-80μM, and have a good effect on promoting cell survival. From the results of Table 2, it can be seen that the representative compounds 9a-9s of the present invention can inhibit H2O2-induced oxidative damage to varying degrees and have good antioxidant activity. Among them, compound 9r has the best protective activity, with a neuroprotective rate of 55.61%. It can be seen from Table 3 that compounds 9a-9s have a certain inhibitory activity on NMDA-induced excitatory damage. Among them, compound 9c has the best activity against excitatory damage, and its neuroprotective rate is 38.07%.

[0170] Table 1 Compounds 9a-9s promote proliferation and growth of SH-SY5Y cells

[0171]

[0172]

[0173] Table 2 Effects of compounds 9a-9s on H2O2-induced oxidative damage in SH-SY5Y cells

[0174]

[0175] Table 3 Effects of compounds 9a-9s on NMDA-induced excitotoxicity in SH-SY5Y cells

[0176]

[0177]

[0178] 7. Observe cell morphology changes under an inverted microscope

[0179] After SH-SY5Y cells were cultured in 96-well plates for 24 hours, the corresponding concentrations of compounds 9c and 9r were prepared in the culture medium to pretreat the cells for 2 hours. SH-SY5Y cells were treated with 200 μM H2O2 in serum-free culture medium or 2 mM NMDA in magnesium-free extracellular solution (H2O2 treatment time was 2 hours, NMDA treatment time was 0.5 hours), and three replicate wells were set for each group. After treatment, the cells were replaced with complete RPMI-1640 culture medium containing 10% fetal bovine serum and continued to be cultured for 24 hours. Changes in cell morphology were observed using a microscope.

[0180] As attached Figure 2 As shown in Figure 2, the representative compound 9r can significantly inhibit the death of SH-SY5Y cells induced by H2O2 and promote the proliferation and survival of undamaged cells. Fig. 9 As shown, the representative compound 9c can significantly inhibit the death of SH-SY5Y cells induced by NMDA and promote the proliferation and survival of undamaged cells.

[0181] 8 Flow cytometry to detect cell apoptosis

[0182] Cell apoptosis was detected using the FITC Annexin V apoptosis detection kit (Cat. No. 556547, BD Biosciences, USA). The treated cells were collected and made into a cell culture medium with a density of about 1×10 6 The single cell suspension was prepared with 5 μL Annexin V-FITC and 5 μL PI dye solution with binding buffer, and the dye solution and cell solution were mixed and incubated for 30 minutes in the dark. The cell apoptosis rate was detected by flow cytometry (ACEA Biosciences, San Diego, USA). Figure 3 As shown in Figure 2, the representative compound 9r can significantly inhibit the apoptosis of SH-SY5Y cells induced by H2O2. Fig.10 As shown in the figure, the representative compound 9c can significantly inhibit the apoptosis of SH-SY5Y cells induced by NMDA.

[0183] 9JC-1 and ROS kit detection experiment

[0184] According to the instructions, the generation of ROS was detected using a reactive oxygen species analysis kit (Beyotime Biotech). The cells were taken, washed with PBS, and DCFH-DA (10 μM) serum-free RPMI / 1640 culture medium was added, incubated at 37°C for 30 min, and the effect of 9r on the mitochondrial membrane potential of cells treated with H2O2 was detected using an inverted fluorescence microscope and flow cytometer. Mitochondrial membrane potential was determined according to the instructions. Using JC-1 working solution, staining was performed at 37°C for 20 min, washed 3 times in PBS, and the effect of 9r on the mitochondrial membrane potential of cells treated with H2O2 was detected using an inverted fluorescence microscope and flow cytometer.

[0185] The results are attached Figure 5 And attached Figure 6 As shown in Figure 2, mitochondrial membrane potential and ROS were significantly increased in the hydrogen peroxide-treated group compared with the control group. However, 9r pretreatment antagonized the effects of H2O2 on mitochondrial membrane potential and ROS (Supplementary Figure 2). Figure 5 The compound 9r of the present invention can protect the mitochondrial membrane potential and reduce the production of JC-1 induced by H2O2 (see Appendix Figure 6 ).

[0186] 10. Detection of changes in related proteins by immunoblotting

[0187] The treated cells were collected, proteins were extracted with protein lysis buffer and the extracted proteins were quantified with BCA working solution. 40 μg-80 μg of protein were separated by polyacrylamide gel electrophoresis, and then blocked with BSA for 2 hours on protein transfer paper PVDF membrane, followed by incubation with primary antibody and secondary antibody. The imaging analysis was performed using the Bio-RedChemiDocMP imaging system.

[0188] By the attached Figure 4 It can be seen that pretreatment with the compound 9r of the present invention can reduce the expression level of pro-apoptotic proteins induced by H2O2. Fig.11 It can be seen that pretreatment with compound 9c of the present invention can reduce the expression level of pro-apoptotic proteins induced by NMDA. Figure 7 As shown in Figure 2, the representative compound 9r activated the IL-6 pro-survival signaling pathway, upregulated the expression levels of pro-survival proteins (IL-6, p-Stat3, and p-Src), and promoted the proliferation and survival of SH-SY5Y cells that were not damaged by H2O2. Figure 8 As shown, compound 9r exerts antioxidant activity by promoting the nuclear translocation of Nrf2 and upregulating the protein levels of Nrf2 and downstream HO-1.

[0189] By the attached Fig.12 The results show that the representative compound 9c with the best anti-excitotoxic activity inhibited NMDA-induced excitotoxicity in SH-SY5Y cells by reducing the protein level of NR2B and increasing the expression levels of AMPA and downstream p-mTOR. In addition, the representative compound 9c with the best anti-excitotoxic activity alleviated the damage of NMDA to SH-SY5Y cells and promoted the proliferation and survival of SH-SY5Y cells by activating the IL-6 pro-survival pathway and the Nrf2 antioxidant pathway (see Appendix). Fig.13 ).

Claims

1. A 1,4-disubstituted piperazine-2,5-dione derivative, characterized in that: The chemical structure is shown in Formula I: The R1 is: 3,5-dimethoxyphenyl, 3,4-methylenedioxyphenyl, phenyl, 3-methoxyphenyl, or 4-methoxyphenyl; the R2 is: p-methoxyphenyl, p-methylphenyl, phenyl, p-fluorophenyl, p-trifluoromethylphenyl, p-tert-butylphenyl, methyl, m-bromophenyl, ethyl, propyl, 3,5-difluorophenyl, tert-butyl, cyclopropyl, methoxy or cyclopentylethyl.

2. The method for preparing the 1,4-disubstituted piperazine-2,5-dione derivative according to claim 1, characterized in that: The chemical reaction formula is as follows: The reaction conditions are as follows: (a) ethyl bromoacetate, potassium carbonate, anhydrous acetone, 60°C; (b) chloroacetyl chloride, dichloromethane / water, potassium carbonate, tetrabutylammonium hydrogen sulfate, room temperature; (c) sodium azide, N,N-dimethylformamide, 90°C; (d) triphenylphosphine, tetrahydrofuran, water, room temperature; (e) acyl chloride (8), 4-dimethylaminopyridine, dichloromethane, 0°C, room temperature; The preparation method comprises the following steps: (1) Using 1a-e and ethyl bromoacetate as raw materials and acetone as solvent, intermediates 2a-e were prepared; (2) using the intermediate 2a-e prepared in step (1) and chloroacetyl chloride as raw materials, tetrabutylammonium hydrogen sulfate as a catalyst, and dichloromethane and water as solvents to prepare intermediate 3a-e; (3) Using the intermediate 3a-e prepared in step (2) and sodium azide as raw materials and N,N-dimethylformamide as solvent, intermediate 4a-e was prepared; (4) Using the intermediate 4a-e prepared in step (3) and triphenylphosphine as raw materials, tetrahydrofuran and water as solvents, intermediate 7a-e is prepared; (5) Using the intermediate 7a-e prepared in step (4) and different acid chlorides (8) as raw materials, triethylamine as an acid binding agent, 4-dimethylaminopyridine as a catalyst, and dichloromethane as a solvent, the target compounds 9a-s are prepared; 3. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2, characterized in that: In the step (1), the aromatic amine compound 1a in the aromatic amine compounds 1a-e is 3,5-dimethoxyaniline, the aromatic amine compound 1b is 3,4-methylenedioxyaniline, the aromatic amine compound 1c is aniline, the aromatic amine compound 1d is 3-methoxyaniline, and the aromatic amine compound 1e is 4-methoxyaniline; wherein the molar ratio of the aromatic amine compounds 1a-e, anhydrous potassium carbonate and ethyl bromoacetate is 1:1.5:1.3; 4. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2, characterized in that: In the step (2), the molar ratio of chloroacetyl chloride, intermediate compound 2a-e, anhydrous potassium carbonate and tetrabutylammonium hydrogen sulfate is 1.5:1:1.5:0.

1.

5. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2, characterized in that: In the step (3), the molar ratio of sodium azide to amide compound 3a-e is 2.5:

1.

6. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2, characterized in that: In the step (4), the molar ratio of the azide compound 4a-e to triphenylphosphine is 1:1.

5.

7. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2, characterized in that: In the step (5), the chloride is the acyl chloride (8), the molar ratio of the intermediate compound 7a-e, 4-dimethylaminopyridine and triethylamine is 1.3:1:0.1:

2.

8. The method for preparing a 1,4-disubstituted piperazine-2,5-dione derivative according to claim 2 or 7, characterized in that: The acyl chloride (8) is one of the following compounds:

9. A use of the 1,4-disubstituted piperazine-2,5-dione derivative as claimed in claim 1, characterized in that: The derivative is used in preparing drugs for promoting cell survival, resisting oxidation and inhibiting NMDA-induced excitatory damage.

Citation Information

Patent Citations

  • Asymmetric acyl-protected 2,5-diketopiperazine derivative and preparation method and application thereof

    CN104356077A